Eikon Therapeutics stock price rises 6%, multiple brokerages initiate coverage research

LootboxPhobia · 2026-03-03T06:46:23+00:00

Eikon Therapeutics stock rises 6% as multiple Wall Street brokerages give bullish ratings. The company focuses on cancer drug development, with its EIK1001 candidate showing promising efficacy. The high-resolution microscopy discovery platform is well regarded, driving candidate drug generation.

LootboxPhobia

2026-03-03 06:46:23

Abstract generation in progress

Investing.com – Drug developer Eikon Therapeutics (NYSE:EIKN) stock rose 6% to $14.65 on Monday, after at least five Wall Street brokerages initiated coverage and issued bullish ratings following the end of the IPO quiet period. Wedbush issued a negative rating in its report on February 26.

J.P. Morgan stated that Eikon’s product portfolio strategy is clear, with licensing bringing in two advanced assets, and its discovery engine built through its super-resolution microscopy. The company is led by senior Merck & Co. executive Roger Perlmutter, with a team including former Merck executives involved in the development of Keytruda.

The company’s most advanced candidate, EIK1001, is being used in combination with Keytruda in a mid-to-late stage study to treat a type of skin cancer. According to data from Morgan Stanley, the Phase 2 results of EIK1001 combined with Keytruda and chemotherapy showed an objective response rate of 60% in first-line non-small cell lung cancer, with 71% in squamous cell carcinoma and 56% in non-squamous cell carcinoma.

Bank of America Securities highlighted Eikon’s discovery platform, calling it a proprietary high-resolution microscope capable of visualizing proteins in live cells. The company states that this technology can generate candidate drugs for internal development or external licensing.

Morgan Stanley also pointed out the company’s PARP1-selective candidates, EIK1003 and EIK1004. EIK1003 has shown single-agent activity in heavily pretreated breast and ovarian cancers, including a 31% objective response rate in PARP-naive patients.

According to Morgan Stanley, the company’s Werner syndrome helicase inhibitor, EIK1005, moved from a tool compound into clinical trials in less than 18 months and is currently in Phase 1/2 trials.

Eikon went public last month in New York, selling 21.2 million shares at $18 each. J.P. Morgan, Morgan Stanley, Bank of America Securities, Cantor, and Mizuho Securities were the underwriters for the offering.

This article was translated with AI assistance. For more information, see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.